LIXTE Biotechnology Names Sidney Braun CEO of Liora Technologies Europe Subsidiary

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, announced on February 18, 2026 it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary. Braun was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc.

A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. Over his career, Braun played a key role in building an infusion network for the biologic drug Remicade, which was approved to treat several immune-mediated inflammatory diseases. He also created a physician network in Canada that was sold to Toronto-based AIM Health Group. Braun is multi-lingual and holds degrees in economics and business administration from Fordham University.

The CEO stated the appointment of Braun as CEO of Liora is in keeping with the company's plan to bring Liora's LiGHT System technology to the forefront of modern cancer treatment and eventually enable LIXTE to pursue a recurring revenue model. Management said the appointment supports its strategy to scale the technology and pursue a recurring revenue model within the radiotherapy segment of cancer care.

Braun stated he steps into his new role at Liora fully committed to fostering further development in the radiotherapy segment of cancer care to achieve positive patient outcomes and long-term value for LIXTE's shareholders.

Liora is pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. The Company's proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.

LB-100 is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.